肿瘤药物加速审批计划：庆祝生命年已超过 250,000 岁，并且还在继续增加。
The accelerated approval program for oncology drugs: celebrating more than 250,000 life-years gained and counting.
发表日期：2024 Aug 01
作者：
Julie Patterson, John Michael O'Brien, Jonathan D Campbell
来源：
Food & Function
摘要：
本评论探讨了最近发表的两项评估 FDA 肿瘤药物加速审批计划临床效益的研究如何得出不同的结论。
This commentary explores how 2 recently published studies evaluating the clinical benefit of the FDA's accelerated approval program for oncology drugs came to different conclusions.